Search
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especi...
Synonyms: 1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole, 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazoleCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEstrone
go.drugbank.com/drugs/DB00655ApprovedEstrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries,...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesNilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsNicergoline
go.drugbank.com/drugs/DB00699ApprovedAn ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesNateglinide
go.drugbank.com/drugs/DB00731ApprovedNateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalModafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing pe...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesEtodolac
go.drugbank.com/drugs/DB00749ApprovedInvestigationalVet approvedEtodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of sig...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesDactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalAs a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDipyridamole
go.drugbank.com/drugs/DB00975ApprovedInvestigationalA phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 199...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBusulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalBusulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (my...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates